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Abstract
Background:  Asthma  and  Allergic  Rhinitis  (AR)  are  two  chronic  inﬂammatory  diseases  that  are
often concomitant.  The  Control  of  Allergic  Rhinitis  and  Asthma  Test  (CARAT)  was  developed
to evaluate  the  control  of  these  diseases  from  the  patients’  perspective.  Its  performance  in
asthma patients  without  AR  has  not  been  previously  studied.
Aim: To  test  the  hypothesis  that  CARAT  can  be  used  to  assess  asthma  control  in  patients  with
asthma and  without  AR.
Methods:  A  cross-sectional  study  was  conducted  in  3  primary  healthcare  centres  in  Northern
Portugal.  Adult  patients  identiﬁed  in  the  Electronic  Patient  Record  with  a  diagnosis  of  asthma
were invited  to  participate.  CARAT  was  used  to  assess  asthma  control  and  Asthma  Control
Test (ACT)  as  a  comparator.  The  associations  between  asthma  patients  without  AR  (AsAR)  and
with AR  (AwAR)  were  analyzed  with  Spearman  correlation.  Additionally,  Receiver  Operating
Characteristic  (ROC)  curve  analysis,  summarized  by  Area  Under  the  Curve  (AUC),  was  used  toT  for  screening  asthma  that  was  not  well-controlled.
sthma  patients  completed  the  study,  64  (62%)  had  AwAR  and
not  well-controlled.  We  observed  a  strong  correlation  between
 0.734)  in  all  asthma  patients  and  in  both  groups:  AsAR  (r  =  0.737)assess performance  of  CARA
Results:  A  total  of  103  a
in 87  (85%)  asthma  was  
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and  AwAR  (r  =  0.843).  ROC  curve  demonstrated  CARAT  as  having  a  good  discriminative  power
for both  AsAR  and  AwAR  groups  (AUC  =  0.894  and  0.946,  respectively).
Conclusion:  These  initial  results  suggest  that  CARAT  has  a  good  discriminative  performance,
similar to  other  asthma  control  assessment  tools,  for  asthma  patients  with  and  without  AR.
© 2015  Sociedade  Portuguesa  de  Pneumologia.  Published  by  Elsevier  Espan˜a,  S.L.U.  This  is  an
open access  article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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he  ‘‘Allergic  Rhinitis  and  its  Impact  on  Asthma’’  (ARIA)
ighlights  a  close  relationship  between  asthma  and  Aller-
ic  Rhinitis  (AR)  and  recommends  a  combined  approach  to
valuate  and  manage  these  two  conditions.1
The  Control  of  Allergic  Rhinitis  and  Asthma  Test  (CARAT)
as  the  ﬁrst  questionnaire  to  assess  the  level  of  control
f  both  asthma  and  AR  using  a  single  tool.2,3 CARAT  was
eveloped  using  a  thorough  formal  methodological  approach
nd  the  validation  studies  showed  it  has  the  good  measure-
ent  properties  observed  fulﬁlling  the  ten  items  on  the
Onsensus-based  Standards  for  the  selection  of  health  Mea-
urement  Instruments  (COSMIN).3 It  is  a  Patient-Reported
utcome  that  quantiﬁes  the  degree  to  which  therapy  goals
re  met  in  patients  with  a  previous  diagnosis  of  AR  and
sthma  and  can  be  used  at  all  levels  of  care.4--6As  CARAT’s
roperties  have  been  tested  in  patients  with  both  asthma
nd  rhinitis,  the  aim  of  this  study  was  to  test  the  hypothesis
hat  CARAT  can  be  used  to  assess  asthma  control  in  patients
ith  asthma  and  without  AR.
ethods
 cross-sectional  study  was  conducted  in  Caldas  das  Taipas,
 sub-urban  area  of  Northern  Portugal.  All  adult  patients
ared  for  in  one  of  the  three  primary  care  centres  (PCC),
etween  November  and  December  2010,  with  an  asthma
iagnosis  registered  on  the  Electronic  Patient  Record  (EPR),
ere  eligible  for  the  study.  The  exclusion  criteria  were:  mis-
iagnosis/coding  error  conﬁrmed  by  both  the  patient  and
he  family  doctor;  physical  or  cognitive  disabilities  that  pre-
ented  the  completion  of  the  questionnaire;  patients  that
ould  not  attend  an  appointment.  A  letter  was  sent  to  all  eli-
ible  patients,  explaining  the  aim  of  the  project  and  inviting
hem  to  participate.
The  Ethics  Committee  of  the  Regional  Health  Adminis-
ration  approved  the  study.  Written  informed  consent  was
btained  from  each  participant.
Participants  were  classiﬁed  has  having  AR  based  on  the
resence  of  two  or  more  of  ﬁve  symptoms,  as  recommended
y  ARIA  guidelines.1
CARAT  has  10  questions  and  a  rating  scale  from  0  to  30,
ith  a  cut-off  value  of  24  points  to  classify  patients:  not
ell-controlled  (≤24)  and  controlled  asthma  (>24).4 The
sthma  Control  Test  (ACT)7 was  used  as  a  comparator  for
sthma  control  using  a  cut-off  of  >19,  well  controlled,  and
T
0
l
(19,  not  well-controlled.  For  assessing  AR  symptoms,  the
isual  Analog  Scale  (VAS)  was  used,  ranging  from  0  cm  (good)
o  10  cm  (bad),  with  a  cut-off  of  5.5  cm  for  mild  versus  mod-
rate/severe  rhinitis.
Statistical  analysis  was  performed  using  IBM  SPSS  v21
Armonk,  NY;IBM  Corp.).  The  associations  between  CARAT
ith  ACT  scores  in  asthma  patients  without  AR  (AsAR)  and
ith  AR  (AwAR)  were  analyzed  by  Spearman  correlation.
eceiver  Operating  Characteristic  (ROC)  curve  analysis  was
sed  to  assess  the  performance  of  CARAT  score  against  ACT,
ummarized  using  the  Area  Under  the  Curve  (AUC).  A  signif-
cance  level  of  ˛  <  0.05  was  considered.  A  power  analysis  for
 independent  proportions  was  conducted  post  hoc.
esults
f  the  192  patients  identiﬁed  103  participated  --  29  could
ot  be  contacted,  5  refused  to  participate,  20  missed  >1
ppointments,  7  were  misdiagnosed  and  28  (15%)  were
nable  to  complete  the  questionnaire.  The  participation
ate  of  eligible  patients  was  72%.
From  the  103  patients  included,  64  (62%)  had  AwAR
Table  1).  Eighty-seven  participants  (85%)  were  classiﬁed  as
aving  not  well-controlled  asthma  based  on  the  CARAT  score
nd  56  (54%)  by  the  ACT  score.  In  the  group  of  AwAR  a  higher
roportion  were  classiﬁed  as  having  not  well-controlled
sthma  both  by  CARAT  and  ACT,  97%  and  61%,  respectively,
hich  compares  with  64%  and  44%  in  AsAR  group  (Table  1).
There  was  a strong  and  signiﬁcant  correlation  between
CT  and  CARAT  scores  in  all  asthma  patients  (r  =  0.734)
nd  in  both  AsAR  and  AwAR  groups  (r  =  0.737  and  r  =  0.843,
espectively)  (Fig.  1).
The  performance  of  CARAT  for  detecting  not  well-
ontrolled  asthma,  using  ACT  as  comparator  was  plotted  as
OC  curves  and  the  respective  AUC  were  0.885  for  all  asthma
atients,  0.894  for  AsAR  group  and  0.946  for  AwAR  (Fig.  1).
iscussion
his  study  was  the  ﬁrst  to  test  CARAT  for  evaluating  asthma
ontrol  in  patients  without  AR.  Overall  our  results  suggest
hat  CARAT  performed  well  in  assessing  the  level  of  asthma
ontrol  regardless  of  whether  patients  had  rhinitis  or  not.
he  correlations  between  CARAT  and  ACT  were  higher  than
.73  and  the  AUC  higher  than  0.88.  These  were  slightly
ower  than  those  between  Asthma  Control  Questionnaire
ACQ)  and  ACT  (r  =  −0.87  to  −0.89;  AUCs  =  0.85--0.90)  and
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Table  1  Characterization  of  all  asthma  patients  and  in  both  groups:  AsAR  and  (AwAR).
Total
n  =  103
AsAR
n  =  39
AwAR
n  =  64
Gender,  n  (%)
Male  26  (25)  11  (28)  15  (23)
Female 77  (75)  28  (72)  49  (77)
Age, years
Mean  (SD) 49.51  (18.07) 56.87  (17.4) 45.03  (17.07)
Min--Max 18--88 22--88 18--88
Ever smoked,  n  (%)
Yes  19  (18)  8  (20)  11  (17)
No 84  (82)  31  (80)  53  (83)
CARAT score
Median  (IQR)  17  (11--22)  23  (18--26)  13  (10--18)
Asthma overall  control  by  CARAT,  n  (%)
Not well-controlled  87  (85)  25  (64)  62  (97)
Controlled 16  (15)  14  (36)  2  (3)
VAS --  rhinitis,  median  (IQR)  4.8  (0--7.8)  0  (0--0)  5.95  (4.8--8.4)
Mild rhinitis,  n  (%)  65  (64)  35  (92)  30  (47)
Moderate/severe  rhinitis,  n  (%)  37  (36)  3  (8)  34  (53)
ACT score
Median  (IQR)  19  (14--22)  20  (17--22)  18  (13--22)
Asthma control  by  ACT,  n  (%)
Not well-controlled  56  (54)  17  (44)  39  (61)
Controlled 47  (46)  22  (56)  25  (39)
AsAR: asthma without allergic rhinitis; AwAR: asthma with allergic rhinitis; CARAT: Control of Allergic Rhinitis and Asthma Test; ACT:
Asthma Control Test; VAS: Visual Analog Scale; SD: standard deviation; Min--Max: Minimum--Maximum; IQR: interquartile range.
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tFigure  1  Receiver  Operating  Characteristic  (ROC)  curves  and  
not well-controlled  asthma,  in  all  patients  and  both  groups:  AsA
with allergic  rhinitis.  AUC:  Area  Under  the  Curve;  r  de  Spearma
similar  to  those  between  ACQ  and  Asthma  Control  Scoring
System  (ACSS).8--10 The  difference  observed  in  the  proportion
of  control  measured  with  CARAT  and  ACT  was  also  reported
in  a  study  conducted  in  Portuguese  pharmacies,  suggesting
that  CARAT  may  have  more  sensitivity  as  an  asthma  control
screening  test  in  the  community.6 A  possible  explanation
for  the  differences  in  the  classiﬁcation  of  asthma  control
between  CARAT  and  ACT  may  be  the  inclusion  in  ACT  of  the
question  ‘‘How  would  you  rate  your  asthma  control  during
the  past  4  weeks?’’  In  patients  who  do  not  perceive  poor
control,  this  question  may  decrease  the  sensitivity  to  detec-
ting  poor  control.  In  fact,  in  the  Portuguese  Asthma  survey
d
t
v
bespective  correlation  of  CARAT  score  against  ACT,  for  screening
d  AwAR.  AsAR:  asthma  without  allergic  rhinitis;  AwAR:  asthma
 <  0.05.
e  observed  that  88%  of  not  well-controlled  asthma  patients
tated  their  disease  was  controlled  when  answering  a  ques-
ion  similar  to  the  ACT  question.11
The  main  limitation  of  this  study  is  not  having  the  physi-
ian’s  assessment  of  asthma  control  to  compare  with  the
ARAT  score,  however,  this  sample  can  potentially  lead  to
eneralizable  results  which  can  answer  our  study  aim,  as
hese  patients  were  followed  in  primary  care,  by  family
octors.  ACT  is  a  well-known  asthma  control  assessment
ool,  used  frequently  in  Portugal,  even  though  no  clinical
alidation  study  of  the  Portuguese  (European)  version  has
een  published.  The  study  has  an  adequate  statistical  power
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1  −  ˇ  =  0.662)  and  the  participation  rate  was  good  for  this
ype  of  study.  However,  the  sample  size  is  a  limitation  as
t  does  not  allow  for  further  subgroup  analysis.  The  inclu-
ion  of  patients  with  a  registered  diagnosis  of  asthma  in  the
PR  is  both  a  strength  and  limitation  of  the  study,  because
t  reduces  the  probability  of  including  patients  with  dis-
ases  other  than  asthma  (speciﬁcity)  and  at  the  same  time,
any  patients  with  asthma,  perhaps  less  severe  asthma,
ere  probably  not  registered  in  the  EPR.  Finally,  the  high
evel  of  not  well-controlled  asthma  observed  may  be  par-
ially  explained  by  the  study  design.  There  is  a  need  for
tudies  conducted  in  different  healthcare  settings,  in  pri-
ary,  secondary,  tertiary  care  to  assess  the  prevalence  of
ncontrolled  asthma  in  different  situations.
In  conclusion,  the  results  obtained  from  this  study  sup-
ort  the  use  of  CARAT  to  evaluate  the  control  of  asthma  not
nly  in  patients  with  rhinitis  but  also  in  patients  without  AR.
urther  studies  are  needed  to  conﬁrm  the  applicability  of
ARAT  in  asthma  patients  without  rhinitis.
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